ZNTL
Income statement / Annual
Last year (2024), Zentalis Pharmaceuticals, Inc.'s total revenue was $67.43 M,
and the percentage change from the previous year is not available.
In 2024, Zentalis Pharmaceuticals, Inc.'s net income was -$165.84 M.
See Zentalis Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$67.43 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$14,000.00 |
| Cost of Revenue |
$0.00
|
$1.39 M
|
$1.43 M
|
$544,000.00
|
$160,000.00
|
$111,000.00
|
$0.00
|
| Gross Profit |
$67.43 M
|
-$1.39 M
|
-$1.43 M
|
-$544,000.00
|
-$160,000.00
|
-$111,000.00
|
$14,000.00
|
| Gross Profit Ratio |
1
|
0
|
0
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$167.77 M
|
$189.59 M
|
$172.73 M
|
$175.60 M
|
$84.90 M
|
$38.39 M
|
$18.92 M
|
| General & Administrative Expenses |
$87.12 M
|
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$87.12 M
|
$59.40 M
|
$54.55 M
|
$40.94 M
|
$33.89 M
|
$8.46 M
|
$4.88 M
|
| Other Expenses |
$3.74 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$16,000.00
|
$0.00
|
| Operating Expenses |
$258.62 M
|
$252.55 M
|
$227.29 M
|
$216.54 M
|
$118.79 M
|
$46.85 M
|
$23.80 M
|
| Cost And Expenses |
$258.62 M
|
$253.94 M
|
$227.29 M
|
$216.54 M
|
$118.79 M
|
$46.85 M
|
$23.80 M
|
| Interest Income |
$0.00
|
$0.00
|
$2,262.00
|
$1,309.00
|
$1,239.00
|
$498,000.00
|
$355,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.29 M
|
$1.39 M
|
$1.43 M
|
$544,000.00
|
$160,000.00
|
$111,000.00
|
$51,491.00
|
| EBITDA |
-$191.19 M |
-$275.50 M |
-$219.87 M |
-$164.02 M |
-$117.94 M |
-$46.73 M |
-$23.73 M |
| EBITDA Ratio |
-2.84
|
0
|
0
|
0
|
0
|
0
|
-1695.14
|
| Operating Income Ratio |
-2.84
|
0
|
0
|
0
|
0
|
0
|
-1698.79
|
| Total Other Income/Expenses Net |
$25.50 M
|
-$27.90 M
|
$5.99 M
|
$51.98 M
|
$683,000.00
|
$482,000.00
|
$355,000.00
|
| Income Before Tax |
-$165.69 M
|
-$276.89 M
|
-$221.30 M
|
-$164.56 M
|
-$118.10 M
|
-$46.36 M
|
-$23.43 M
|
| Income Before Tax Ratio |
-2.46
|
0
|
0
|
0
|
0
|
0
|
-1673.43
|
| Income Tax Expense |
$177,000.00
|
-$601,000.00
|
-$469,000.00
|
-$297,000.00
|
$444,000.00
|
$15,000.00
|
$4,000.00
|
| Net Income |
-$165.84 M
|
-$292.19 M
|
-$220.83 M
|
-$164.26 M
|
-$118.55 M
|
-$46.38 M
|
-$21.07 M
|
| Net Income Ratio |
-2.46
|
0
|
0
|
0
|
0
|
0
|
-1504.79
|
| EPS |
-2.33 |
-4.47 |
-4.18 |
-3.85 |
-2.89 |
-1.29 |
-1.17 |
| EPS Diluted |
-2.33 |
-4.47 |
-4.18 |
-3.85 |
-2.89 |
-1.29 |
-1.17 |
| Weighted Average Shares Out |
$71.08 M
|
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Weighted Average Shares Out Diluted |
$71.08 M
|
$65.41 M
|
$52.86 M
|
$42.69 M
|
$41.04 M
|
$35.88 M
|
$18.06 M
|
| Link |
|
|
|
|
|
|
|
